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B- and T-lymphocyte precursors follow analo-
gous paths as they differentiate in the bone mar-
row and thymus, respectively: both progress 
through a defined sequence of developmental 
stages, during which entry into and exit from the 
cell cycle must be tightly and dynamically regu-
lated (Rothenberg, 2014). A critical step in both 
pre–B and pre–T cell development is a clonal 
proliferative expansion after transient surface 
expression of a pre–B cell receptor (pre–BCR) or 
pre–T cell receptor (pre–TCR), indicating suc-
cessful gene rearrangements at  heavy chain or 
TCR- loci, respectively (Muljo and Schlissel, 
2000). After this burst of proliferation, pre–B and 
pre–T cells must then exit the cell cycle to allow 
further differentiation, namely the rearrange-
ment of  light or TCR- chains en route to 
expressing a functional antigen receptor (Michie 
and Zuñiga-Pflucker, 2002; Clark et al., 2014).
One of the primary effectors of these pro-
cesses is Cyclin D3, which plays essential and 
nonredundant roles in the proliferation of both 
pre–B and pre–T cells (Sicinska et al., 2003; 
Cooper et al., 2006; Sawai et al., 2012). The 
precise molecular mechanisms by which these 
cells transition from a proliferative state to a qui-
escent one are still being dissected. Transcrip-
tional repression of Cyclin D3 (Mandal et al., 
2009) and other cell cycle–associated genes 
(Hoffmann et al., 2002) occurs; however, little is 
known about the regulation of Cyclin D3 pro-
tein stability during this transition. The ubiqui-
tin–proteasome system allows cells to rapidly 
diminish the quantity of certain proteins avail-
able for cell cycle progression. To initiate this 
mechanism, proteins must first be phosphory-
lated at specific residues within phosphodegrons 
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Pre–B and pre–T lymphocytes must orchestrate a transition from a highly proliferative 
state to a quiescent one during development. Cyclin D3 is essential for these cells’ prolif-
eration, but little is known about its posttranslational regulation at this stage. Here, we 
show that the dual specificity tyrosine-regulated kinase 1A (DYRK1A) restrains Cyclin D3 
protein levels by phosphorylating T283 to induce its degradation. Loss of DYRK1A activity, 
via genetic inactivation or pharmacologic inhibition in mice, caused accumulation of Cyclin 
D3 protein, incomplete repression of E2F-mediated gene transcription, and failure to 
properly couple cell cycle exit with differentiation. Expression of a nonphosphorylatable 
Cyclin D3 T283A mutant recapitulated these defects, whereas inhibition of Cyclin D:
CDK4/6 mitigated the effects of DYRK1A inhibition or loss. These data uncover a  
previously unknown role for DYRK1A in lymphopoiesis, and demonstrate how Cyclin D3 
protein stability is negatively regulated during exit from the proliferative phases of B and  
T cell development.
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Peripheral blood B cell, but not neutrophil, numbers 
were reduced in CKO mice at 2 and 4 wk after pI:pC (un-
published data). In the bone marrow, total cellularity in the 
CKO mice was unchanged compared with controls at 2 and 
4 wk after pI:pC (Fig. 2 A). Within the B cell lineage, the 
percentage of pro–B cells (IgM/B220+/CD43+/cKit+) was 
unchanged; however, we observed a two- to threefold reduc-
tion in the percentage and absolute number of pre–B cells 
(IgM/B220+/CD43low/; Fig. 2, B and C). This population 
contains both rapidly cycling large pre–B cells (IgM/B220+/
CD43low/FSChigh) and quiescent small pre–B cells (IgM/
B220+/CD43/FSClow). The reduced number of pre–B cells 
in CKO bone marrow primarily reflected a loss of small pre–
B cells (Fig. 2, B and C), suggesting a defect in the large-to-
small pre–B transition. Consistent with this prediction, CKO 
pre–B cells expressed lower surface levels of the differentia-
tion marker CD25 (Fig. 2 D). Later stages of B cells were also 
reduced in numbers in CKO bone marrow, including imma-
ture B (IgM+/IgD/B220+) and mature recirculating B cells 
(IgM+/IgD+/B220high; Fig. 2 C). In contrast, myeloid cells 
were not decreased after loss of Dyrk1a; in fact, the numbers 
of Gr1+/Mac1+ granulocytes modestly increased with time 
(unpublished data).
In accord with the lack of an effect on myeloid develop-
ment, ex vivo myeloid colony-forming ability in cytokine-
supplemented methylcellulose was similar in both control and 
CKO bone marrow in terms of colony number and morphol-
ogy (Fig. 2 E). However, loss of Dyrk1a severely impaired 
pre–B colony formation in cultures containing IL-7 (Fig. 2 E). 
We observed the same phenomenon when we cultured WT 
bone marrow in the presence of the small molecule DYRK1A/B 
inhibitor, EHT 1610 (Foucourt et al., 2014a,b); pre–B colony 
formation was completely blocked at inhibitor concentrations 
that did not affect myeloid colony formation (Fig. 2 F). IL-7 
signaling, which drives pre–B cell expansion both in vivo and 
in ex vivo colony assays, was intact, as loss of Dyrk1a did not 
markedly change surface IL7R expression (Fig. 2 G) or intra-
cellular STAT5 activation (Fig. 2 H).
In addition to a loss of small pre–B cells in the bone mar-
row, thymic pre–T cells were also adversely affected in the CKO 
mice. Total thymocyte cellularity was reduced 5–10 fold after 
loss of Dyrk1a (Fig. 3 A). CD4/CD8 double-negative (DN) 
cells were relatively enriched among the remaining CKO thy-
mocytes compared with controls (Fig. 3 B). Similar to what 
we observed for the B lineage, proliferating DN3 (CD44/
CD25+) and DN4 (CD44/CD25) thymocytes were pres-
ent in similar numbers to controls, but a substantial loss in 
cellularity occurred at the next stage of development, as thy-
mocytes become CD4+/CD8+ double-positive (DP) cells and 
exit the cell cycle (Fig. 3 C). This loss was accompanied by 
a fourfold increase in apoptosis of DP thymocytes (Fig. 3 D). 
Apoptosis in pre–B cells was not affected, as measured by 
either Annexin V or cleaved Caspase 3 staining (unpublished 
data). Thus, the loss of Dyrk1a affects similar developmental 
stages within the B and T lineages, namely, the transition from 
a highly proliferative state to a quiescent one.
(Ye et al., 2004). This phosphorylation facilitates polyubiquity-
lation of the proteins by ubiquitin ligases, which targets them 
for swift degradation by the proteasome (Teixeira and Reed, 
2013). All three D-type Cyclins (D1, D2, and D3) contain 
phosphodegrons that can be targeted by various kinases to ini-
tiate protein turnover (Casanovas et al., 2004; Naderi et al., 
2004; Låhne et al., 2006; Barbash et al., 2009); however, the 
identities and relative contributions of the kinases that specifi-
cally regulate Cyclin D3 stability during lymphoid develop-
ment remain unclear.
Dual specificity tyrosine-regulated kinase 1A (DYRK1A) 
has been shown to phosphorylate more than 30 proteins to 
regulate diverse biological functions, including synaptic trans-
mission (Xie et al., 2012; Chen et al., 2014), neurodegen-
eration (Wegiel et al., 2011), transcription (Gwack et al., 
2006), mRNA splicing (de Graaf et al., 2006), proliferation 
(Hämmerle et al., 2011; Litovchick et al., 2011; Chen et al., 
2013), and survival (Guo et al., 2010; Barallobre et al., 2014). 
DYRK1A phosphorylates Cyclin D1 on threonine 286 (T286) 
to promote its degradation and subsequent cell cycle arrest in 
developing neurons (Yabut et al., 2010; Soppa et al., 2014) 
and fibroblasts (Chen et al., 2013). Recent work in our labo-
ratory uncovered a tumor-promoting role for DYRK1A in the 
megakaryocytic leukemia associated with Down syndrome 
(Malinge et al., 2012); this was the first report of DYRK1A’s 
importance in a hematopoietic cell type. To understand how 
DYRK1A functions during hematopoiesis, we conditionally 
inactivated the gene using the Mx1-Cre, Lck-Cre, and CD19-
Cre LoxP systems. Here, we reveal that DYRK1A phosphory-
lates Cyclin D3 to decrease its stability in pre–B and pre– 
T cells and promote quiescence during the large-to-small 
pre–B, and double negative-to-double positive thymocyte 
transitions. Loss of DYRK1A results in Cyclin D3 stabiliza-
tion and failure to repress E2F target genes, which ultimately 
impairs cell cycle exit and proper differentiation of pre–B and 
pre–T cells.
RESULTS
Dyrk1a is selectively required for lymphopoiesis
To achieve conditional inactivation of Dyrk1a, we generated 
a Dyrk1a allele with loxP sites flanking (floxed) exons 5 and 6, 
which encode an essential portion of the protein’s kinase do-
main (Fig. 1 A). The frameshift caused by loss of exons 5 and 6 
allows for potential expression of a truncated 12.5-kD pro-
tein; however, if expressed it would lack most of the essential 
functional domains of DYRK1A.
Mice with the floxed allele were crossed to Mx1-Cre trans-
genic mice to generate Dyrk1a conditional knockout (Dyrk1af/f 
Mx1-Cre+, referred to hereafter as CKO) animals. To induce 
Cre expression and subsequent excision at the Dyrk1a locus 
in all hematopoietic cells, we treated animals with four in-
jections of polycytidylic:polyinosinic acid (pI:pC). Loss of 
DYRK1A expression in the bone marrow and thymus 2 wk 
after pI:pC was confirmed at the genomic (Fig. 1 B), mRNA 
(Fig. 1 C), and protein levels (Fig. 1 D).
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expression) indicates a selective pressure against loss of Dyrk1a  
in this system. In contrast, we typically achieved 95–99% re-
duction in Dyrk1a mRNA in CKO cells using Mx1-Cre or 
Lck-Cre (Fig. 1 C and not depicted).
The requirement for Dyrk1a is cell autonomous
Because the Mx1-Cre system also results in deletion of target 
sequences within bone marrow stromal cells, we next in-
vestigated whether the phenotype of Dyrk1a loss is cell auton-
omous. To address this point, we performed competitive 
bone marrow transplantation experiments. CD45.2-expressing 
Dyrk1af/f Mx1-Cre (Control) or Dyrk1af/f Mx1-Cre+ (CKO) 
bone marrow cells before pI:pC treatment were mixed 1:1 
with congenic WT CD45.1 bone marrow cells and then trans-
planted into lethally irradiated CD45.1 recipient mice. Hema-
topoietic reconstitution of peripheral blood was confirmed 
4 wk after transplant (Fig. 4 A). Subsequently, mice were treated 
with pI:pC to inactivate Dyrk1a in CKO cells, and analyzed 
To validate our observations using a different Cre driver, 
we crossed Dyrk1af/f mice to the Lck-Cre strain, which in-
duces gene excision beginning at the DN3 stage of thymic 
development and leads to nearly complete excision by the 
DP stage (Hennet et al., 1995). The thymi of Dyrk1af/f Lck-Cre+ 
mice mirrored those from Dyrk1af/f Mx1-Cre+ mice, showing 
marked hypocellularity and loss of DP thymocytes (Fig. 3, 
E and F). Separately, we crossed Dyrk1af/f mice to CD19-Cre 
mice to delete DYRK1A exclusively in the B lineage. Be-
cause this system is known to give inefficient excision at 
the pre–B cell stage (Hobeika et al., 2006), we crossed in a 
ROSA26lox-STOP-lox-EGFP allele (Mao et al., 2001) to follow the 
cells that have undergone Cre-mediated excision. Surpris-
ingly, flow-purified EGFP+ pre–B cells from Dyrk1af/f CD19-
Cre+/ EGFP+/ mice still expressed considerable levels of 
Dyrk1a (40–50% of that in control cells; unpublished data). 
The fact that Cre-expressing pre–B cells excised one locus 
(i.e., became EGFP+), but not another (i.e., retained Dyrk1a 
Figure 1. Conditional inactivation of the 
Dyrk1a gene. (A) Exons 5 and 6 were floxed 
in the targeted allele and excised in the con-
ditional knockout (CKO) allele. (B) PCR from 
thymocyte genomic DNA was performed 2 wk 
after pI:pC treatment using the indicated 
primers in A (i and ii) and assessing the pres-
ence or loss of the targeted allele in Dyrk1af/f 
Mx1-Cre, Dyrk1af/w Mx1-Cre+, and Dyrk1af/f 
Mx1-Cre1+,mice. (C) Dyrk1a mRNA expression 
measured by qRT-PCR using primers within 
the excised gene segment in bone marrow 
and thymus for the indicated mice. (D) West-
ern blot shows DYRK1A protein expression in 
bone marrow and thymus after loss of 0, 1,  
or 2 Dyrk1a alleles. Densitometry values were 
normalized to HSC70. Loss of DYRK1A expres-
sion was verified for all subsequent experi-
ments by qPCR, Western blot, or both. Data 
are derived from 1 litter and are representa-
tive of over 20 cohorts that were analyzed by 
RT-PCR and/or Western blot.
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thymocytes, but total pre–B cell and thymocyte numbers were 
significantly reduced in these recipients, recapitulating the phe-
notypes described in Figs. 2 and 3 (unpublished data). These 
data confirm that loss of Dyrk1a causes a cell-autonomous de-
fect in lymphoid development.
2 wk later. Whereas control CD45.2 cells provided 30–50% 
donor chimerism in the bone marrow and thymus, we observed 
no contribution to B or T cell development from CKO cells 
(Fig. 4, B and C). Transplantation of CKO cells at fourfold ex-
cess provided variable donor chimerism in pre–B cells and 
Figure 2. Loss of Dyrk1a adversely affects B cell development. (A) Mean bone marrow cellularity was assessed in Dyrk1af/f Mx1-Cre (Control) and 
Dyrk1af/f Mx1-Cre+ (CKO) mice 2 and 4 wk after pI:pC treatment; n = 6 mice per genotype, pooled from 3 independent cohorts of 2 mice per genotype.  
(B) Representative flow cytometry analysis of bone marrow for total pre–B (IgM gate, left) and large/small pre–B (pre–B gate, right) cells 4 wk after pI:pC 
treatment is shown. Numbers indicate percentages in each gate; mean percentages of each population among total bone marrow cells were quantified in 
(C); n = 6 mice per genotype, pooled from 3 independent cohorts of 2 mice per genotype. (D) Representative flow cytometry analysis of pre–B cell surface 
CD25 expression in bone marrow from Control and CKO mice 2 wk after pI:pC treatment is shown; n = 6 mice per genotype, pooled from 3 independent 
cohorts of 2 mice per genotype. (E) Mean number of colony forming units from total bone marrow 2 wk after pI:pC treatment as percent of Control for 
each colony type was calculated; n = 3 mice per genotype, with duplicate plates for each mouse. Data are representative of three independent experi-
ments. (F) The mean numbers and phenotypes of colonies formed by WT bone marrow in the presence of indicated concentrations of EHT 1610 were cal-
culated. Results depict duplicate plates for each condition, and represent 3 independent experiments. (G) Surface IL7R- expression (H) and intracellular 
STAT5 phosphorylation (Y694, C) in small and large pre–B cells from the bone marrow of Control and CKO mice 2 wk after pI:pC treatment were assessed 
by flow cytometry. Data are representative of 3three mice per genotype. For all graphs, error bars depict SD. **, P < 0.01; ****, P < 0.0001.
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discriminator (unpublished data). Furthermore, BrdU incor-
poration experiments revealed multiple cell cycle abnor-
malities. CKO small pre–B cells and DP thymocytes were 
significantly enriched for cells that had entered S-phase (i.e., 
incorporated BrdU) during the pulse (Fig. 5 D). In addition, 
every population analyzed, including granulocytes, contained 
significantly more cells in G2-M at the end of the 24-h pulse 
(i.e., 4N, did not incorporate BrdU), indicating a delay in the 
completion of mitosis in DYRK1A-defcient cells (Fig. 5 D). 
We tested the ability of CKO pre–B cells to undergo pro-
gressive rounds of cell division by labeling FACS-purified large 
pre–B cells with CellTrace dye and monitoring dye dilution 
over time in cultures containing IL-7. Despite the increased 
steady-state fraction of cycling CKO large pre–B cells, they 
Dyrk1a-deficient pre–B and pre–T cells  
fail to become quiescent
Given that Dyrk1a loss affected pre–B and pre–T cells at de-
velopmental stages that are characterized by cell cycle exit 
after a burst of proliferation, we wondered whether Dyrk1a 
regulates quiescence in these populations. Cell cycle analysis 
revealed that, although the vast majority of control pre–B 
and DP thymocytes were in the G0 phase, a substantial frac-
tion of both populations remained in S-G2-M in CKO mice 
(Fig. 5, A–C). However, not all hematopoietic cell popula-
tions were similarly affected: for example, the G0 fraction of 
Gr1high/Mac1high mature granulocytes was not significantly 
changed after loss of Dyrk1a (Fig. 5, A and C). We confirmed 
these findings using intracellular Ki67 staining as a G0/G1 
Figure 3. Loss of Dyrk1a adversely affects T cell development. (A) Mean thymocyte numbers in Control and CKO mice were assessed 2 and 4 wk 
after pI:pC treatment; n = 6 mice per genotype, pooled from 3 independent cohorts of 2 mice per genotype. (B) Representative flow cytometry analysis of 
total (left) and CD4/CD8 double-negative (DN, right) thymocytes is shown. Numbers indicate the percentages in each gate; mean absolute numbers 
were quantified in (C); n = 6 mice per genotype, pooled from 3 independent cohorts of 2 mice per genotype. (D) Mean percentage of Annexin V+ cells was 
assessed from CD4+CD8+ double-positive (DP) thymocytes 2 wk after pI:pC treatment; n = 4 mice per genotype. Data are representative of 2 independent 
cohorts of n = 4 mice per genotype. (E) Mean total thymocyte numbers and representative flow cytometry analysis (F) of thymi from Dyrk1awt/wt Lck-Cre+ 
(Control) and Dyrk1af/f Lck-Cre+ (CKO) mice are shown; n = 6 mice per genotype, pooled from 3 independent cohorts of 2 mice per genotype. **, P < 0.01; 
****, P < 0.0001.
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factor binding sites within the promoters of the shared up-
regulated genes was E2F. E2F factors are considered master 
regulators of cell cycle–dependent transcription: before cell 
cycle entry, Cyclin–CDK complexes phosphorylate the reti-
noblastoma protein (Rb), which releases activator E2Fs to 
induce transcription of genes necessary for cell cycle progres-
sion (Lees et al., 1993; Wu et al., 2001).
The RNA-seq data indicated that E2F target genes are 
expressed at aberrantly high levels in Dyrk1a-deficient quies-
cent small pre–B cells and DP thymocytes. We validated these 
findings in independent cohorts of mice by sorting identical 
populations and interrogating the expression levels of E2F 
target genes by qRT-PCR. As expected, all E2F targets tested 
were expressed at higher levels in WT cycling cells compared 
with WT quiescent ones (unpublished data). Strikingly, E2F 
targets were de-repressed in CKO small pre–B cells (Fig. 6 C) 
and quiescent DP thymocytes (Fig. 6 D) compared with con-
trols. In contrast, expression levels of these genes in CKO large 
pre–B cells (Fig. 6 E) and cycling DP thymocytes (Fig. 6 F) 
were similar to controls. Thus, loss of Dyrk1a leads to a 
failure to repress cell cycle–dependent gene transcription as 
pre–B and pre–T cells attempt to enter quiescence.
Loss of DYRK1A activity alters a subset of differentiation 
makers without affecting pre–BCR signaling
Cell cycle exit is tightly coupled to the differentiation of pre–B 
and pre–T cells. Thus, we next investigated whether failed cell 
cycle exit would coincide with failure to initiate transcriptional 
hallmarks of B cell differentiation in the absence of DYRK1A 
activity. Through our RNA-seq study, we noted that several 
transcripts that are normally repressed at the large-to-small 
pre–B transition (Parker et al., 2005; Schuh et al., 2008), includ-
ing Dntt and the pre–BCR components Vpre–B1 and Igll1, re-
mained elevated in CKO small pre–B cells (Fig. 7 A). Likewise, 
markers normally up-regulated during this transition (Schuh 
completed fewer cell divisions than control large pre–B cells 
(Fig. 5 E). We obtained similar results when culturing WT 
pre–B cells in the presence of EHT 1610 (unpublished data). 
Finally, thymocytes from Dyrk1af/f Lck-Cre+ mice (Fig. 5, 
F and G) displayed similar cell cycle abnormalities, demon-
strating that the cell cycle defects we observed in the Mx1-Cre 
model were not simply due to an artifact of that system.
DYRK1A regulates expression of E2F target genes
To gain insights into the mechanism by which Dyrk1a loss affects 
lymphopoiesis, we performed RNA-sequencing (RNA-seq) 
of multiple hematopoietic cell populations, including B cells, 
thymocytes, and mature granulocytes. We used fluorescence-
activated cell sorting (FACS) to isolate five highly purified 
populations for RNA-seq analysis: quiescent DP thymocytes, 
cycling DP thymocytes, quiescent small pre–B cells, cycling 
large pre–B cells, and mature granulocytes. We generated lists 
of transcripts that were up- or down-regulated in CKO ver-
sus control cells, and then performed gene functional enrich-
ment analysis using DAVID bioinformatics resources (Huang 
et al., 2007). Among the lists of up- and down-regulated tran-
scripts in each of the five cell populations, only two popula-
tions showed enrichment of cell cycle, proliferative, and mitotic 
related terms: up-regulated transcripts in small pre–B cells, and 
up-regulated transcripts in quiescent DP thymocytes. In con-
trast, no significant enrichment of proliferative, mitotic, or cell 
cycle terms was observed in either the cycling cell popula-
tions or the granulocytes.
Among the up-regulated transcripts specific to small pre–B 
cells and quiescent DP thymocytes, 177 were shared (Fig. 6 A). 
In contrast, there were only 15 commonly down-regulated 
transcripts (Fig. 6 B). DAVID analysis of the 177 shared up-
regulated transcripts revealed highly significant enrichments 
for terms associated with cell cycle, DNA replication, and 
mitosis. Furthermore, the top hit for known transcription 
Figure 4. Genetic deletion of Dyrk1a results in cell autonomous loss of competitiveness in lymphoid cells. Total bone marrow cells from either 
Dyrk1af/f Mx1-Cre (Control CD45.2) or Dyrk1af/f Mx1-Cre+ (CKO CD45.2) were mixed with an equal number WT CD45.1 bone marrow cells and trans-
planted into lethally irradiated recipients, which were treated with pI:pC 4 wk later. (A) Mean peripheral blood chimerism (pre–pI:pC treatment) of trans-
planted mice analyzed by flow cytometry for surface CD45 isoform expression 4 wk after transplant is shown; n = 5 mice per group; error bars depict SD. 
(B and C) Donor chimerism in thymocytes (B) and bone marrow B cell populations (C) 2 wk after pI:pC treatment was assessed. Each triangle represents 
one mouse. n = 5 mice per group; error bars depict SD. Data represent two independent transplant experiments. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
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Figure 5. Loss of Dyrk1a results in failed cell cycle exit during lymphoid development. Cell cycle status of bone marrow and thymocytes from 
Dyrk1af/f Mx1-Cre (Control) and Dyrk1af/f Mx1-Cre+ (CKO) was assessed 4 wk after pI:pC treatment. (A and B) Representative flow cytometry plots de-
picting steady-state cell cycle status using DNA versus RNA content (A) and in vivo BrdU incorporation 24 h after BrdU injection (B) are shown. Numbers 
depict percentages in each gate. (C) The corresponding defined cell cycle phases and mean percentages in G0 are shown from the indicated Control and 
CKO cell types shown in A; n = 6 mice per genotype, pooled from 2 independent cohorts of 3 mice per genotype. (D) The mean percentages of cells in 
each phase of the cell cycle from the indicated Control and CKO cell types in B are shown; n = 4 mice per genotype. Data are representative of 2 indepen-
dent experiments. Significant differences are denoted for each phase to the right of each CKO bar. (E) Flow cytometry was performed using CellTrace dye 
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by staining for surface pre–BCR (Fig. 7 D) or intracellular  
heavy chain (Fig. 7 E). Furthermore, we did not detect any 
changes in the activation of downstream Src family kinases or 
PDK-1 (activated via PI3K; Fig. 7 F). The ERK pathway—
also activated by pre–BCR—was previously shown to pro-
mote cell cycle exit at this stage by repressing Cyclin D3 
transcription (Mandal et al., 2009). ERK activation in CKO 
large pre–B cells was similar to, if not greater than, controls 
(Fig. 7 G), and Ccnd3 (Cyclin D3) transcript levels were 
repressed to the same extent as controls in CKO small pre– 
B cells (Fig. 7 H). Additionally, the pre–BCR–dependent 
et al., 2008), such as Cd2, Cd22, and Il2ra (CD25), remained 
low in CKO small pre–B cells (Fig. 7 B). Quantitative PCR 
using genomic DNA from these cells also revealed lower 
amounts of V-J1 light chain rearrangement, indicating 
a failure to differentiate properly (Fig. 7 C).
Key signals that drive the large-to-small pre–B cell transi-
tion emanate from the pre–BCR (Clark et al., 2014). There-
fore, it remained possible that impaired differentiation and 
cell cycle exit in CKO cells might result from altered pre–
BCR signaling. We did not detect any differences in pre–
BCR expression at the large pre–B stage in CKO mice, either 
dilution in cultured FACS-purified Control and CKO large pre–B cells. Data are representative of two independent experiments. (F) Thymocytes from Con-
trol and CKO mice (Lck-Cre) were stained for DNA and RNA content to assess cell cycle status as in A. Representative flow cytometry plots for DP thymo-
cytes from Control and CKO mice are shown; n = 4 mice per genotype, pooled from 2 independent cohorts of 2 mice per genotype. (G) Mean percentages 
of DP thymocytes in G0 are depicted; n = 4 mice per genotype, pooled from 2 independent cohorts of 2 mice per genotype. For all graphs, error bars  
depict SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; NS, not significant.
 
Figure 6. Dyrk1a-deficient quiescent DP 
thymocytes and small pre–B cells fail to 
repress E2F target gene transcription.  
(A and B) Up- and down-regulated transcripts 
were identified by RNA-sequencing of FACS-
purified quiescent DP thymocytes (CD4+/
CD8+/DNA content2N/Pyronin Ylow), cycling DP 
thymocytes (CD4+/CD8+/DNA content>2N/
Pyronin Yhigh), small pre–B cells (IgM/B220+/
CD43/FSClow), large pre–B cells (IgM/B220+/
CD43low/FSChigh), and granulocytes (Gr-1high/
Mac-1/CD11bhigh) from Dyrk1af/f Mx1-Cre 
(Control) and Dyrk1af/f Mx1-Cre+ (CKO) mice. 
Venn diagrams depict shared up-regulated (A) 
and down-regulated (B) transcripts identified 
by RNA-sequencing in the three quiescent cell 
populations. (C–F) mRNA expression of E2F 
target genes was assessed by qRT-PCR in 
FACS-purified small pre–B cells (C), quiescent 
DP thymocytes (D), large pre–B cells (E), and 
cycling DP thymocytes (F) from Control and 
CKO mice 2 wk after pI:pC treatment. Tran-
script levels were normalized to Actb expres-
sion. PCRs were performed using 3 
independently sorted pairs of samples (each 
with 1 mouse per genotype) for pre–B cells, 
and pooled samples from 3 mice per genotype 
for thymocytes. Error bars depict SD of tripli-
cate wells for representative samples.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS,  
not significant (CKO vs. Control).
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Compared with empty vector-transduced cells, Cyclin D3 
T283A-expressing small pre–B cells contained three- to sev-
enfold higher levels of the same E2F target transcripts that 
were de-repressed in CKO small pre–B cells (Fig. 9 B), and 
likewise had reduced levels of the differentiation markers that 
failed to be up-regulated in CKO small pre–B cells (Figs. 9 C 
and 7 B). Expression of the T283A mutant also resulted in 
increased cell size (unpublished data) and an increased pro-
portion of cells in the S–G2–M phases of the cell cycle com-
pared with cells expressing WT Cyclin D3 or empty vector 
(Fig. 9, D and E).
To induce cell cycle exit in our culture system, we replated 
transduced pre–B cells in medium containing 100-fold lower 
cytokine concentrations for 2 d. In empty vector–transduced 
cells, this yielded a population of 90% small pre–B cells that 
had exited the cell cycle (Fig. 9, D and E). In stark contrast, 
Cyclin D3 T283A-expressing cells failed to exit the cell cycle, 
with 40% of cells remaining in S-G2-M. We observed a similar 
block in cell cycle exit among empty vector–transduced cells 
treated with EHT 1610 during cytokine withdrawal; how-
ever, EHT 1610 treatment had much less of an effect on 
Cyclin D3 T283A-expressing cells, indicating that DYRK1A 
inhibition only minimally potentiates retention in S–G2–M 
within cells that already express stabilized Cyclin D3 (Fig. 9, 
D and E). Concomitant treatment with Palbociclib, a CDK4/6 
inhibitor, mitigated the effects of EHT 1610 on cell cycle exit 
in both empty vector- and Cyclin D3 T283A-expressing cells 
(Fig. 9 E). This result confirms that the inability to exit the 
cell cycle after loss of DYRK1A activity occurs, at least in 
part, via a Cyclin D–CDK4/6-dependent mechanism. To ex-
tend these results to our in vivo model, we treated cohorts of 
Control and CKO mice with either 30 or 150 mg/kg Palbo-
ciclib daily for 1 wk, beginning 1 wk after the last pI:pC injec-
tion. We observed minimal differences in the mice treated 
with 30 mg/kg (not depicted), but saw significant restoration 
of cell cycle exit in CKO DP thymocytes and small pre–B 
cells at the 150 mg/kg dose (Fig. 10, A–C). The percentage 
of small pre–B cells relative to large ones was also restored to 
control levels in Palbociclib-treated CKO mice (Fig. 10 C). 
This coincided with decreased expression of E2F target genes 
(e.g., Cdk1 and E2f8) and increased expression of Cd2 and 
Il2ra in FACS-purified small pre–B cells (Fig. 10 D). Thus, 
Palbociclib treatment allowed CKO cells to both exit the 
cell cycle as well as initiate a small pre–B differentiation pro-
gram, further supported by partially restored surface CD25 
expression (Fig. 10 E) and completely restored frequency of 
 light chain rearrangement (Fig. 10 F). Collectively, these 
data suggest that DYRK1A couples cell cycle exit to differen-
tiation in developing lymphoid cells by targeting Cyclin D3 
for degradation.
DISCUSSION
An essential transition in lymphocyte development is the 
switch from a proliferative phase to quiescence. Our data 
uncover a previously unknown role for DYRK1A during 
this step of pre–B and pre–T cell development, wherein it 
up-regulation of Irf4, Ikzf3 (Aiolos), and Rag1 transcripts oc-
curred normally in CKO small pre–B cells (Fig. 7 I). Thus, 
despite functional pre–BCR signaling, certain hallmarks of the 
differentiation program it induces cannot be fully enforced 
without prior DYRK1A-mediated cell cycle exit.
DYRK1A promotes quiescence  
via phosphorylation of Cyclin D3
We next asked whether E2F deregulation in CKO cells might 
stem from increased Cyclin D–CDK4/6 activity. Cyclin D1, 
although regulated by DYRK1A (Chen et al., 2013; Soppa 
et al., 2014), is expressed at very low or undetectable levels 
during lymphoid development (Cooper et al., 2006; Fig. 8 C). 
Cyclin D3, however, is a critical mediator of proliferation in 
both pre–B and pre–T cells, and is highly expressed in both 
cell types (Sicinska et al., 2003; Cooper et al., 2006). We 
found a dramatic increase in Cyclin D3 protein level in CKO 
large and small pre–B cells, as well as in CKO thymocytes 
(Fig. 8 A), and this correlated with increased phosphorylation 
of Rb at S807/S811 (Fig. 8 B). Cyclin D2 protein, which is 
dispensable for pre–B cell development (Cooper et al., 2006) 
and not expressed in thymocytes after the DN3 stage (Sicinska 
et al., 2003), also accumulated in CKO large pre–B cells 
(Fig. 8 B), although its mRNA expression levels were much 
lower than for Cyclin D3 (Fig. 8 C). Despite the increases in 
Cyclin D3 protein, Ccnd3 transcript levels were not elevated 
in CKO pre–B cells or thymocytes (Figs. 7 H and 8 C). Accu-
mulation of Cyclin D3 protein, but not transcript, suggests that 
it might be stabilized in the absence of DYRK1A. Indeed, cy-
cloheximide pulse-chase experiments showed increased Cyclin 
D3 protein stability in CKO thymocytes (Fig. 8 D).
Because the CKO cells contained much higher steady-
state amounts of Cyclin D3, we also performed these experi-
ments with WT pre–B cells treated acutely with EHT 1610. 
Here, the Cyclin D3 half-life was similarly prolonged in the 
presence of the inhibitor (Fig. 8 E). Cyclin D2 protein stability 
also increased after DYRK1A inhibition, but to a much lesser 
extent than Cyclin D3 (Fig. 8 E). As Cyclin D3 harbors a phos-
phodegron at its C terminus, centered on T283 (Casanovas 
et al., 2004), that is nearly identical to the one phosphorylated 
by DYRK1A in Cyclin D1 (Fig. 8 F), we asked whether 
DYRK1A destabilizes Cyclin D3 by phosphorylating this crit-
ical residue. Indeed, in vitro kinase assays demonstrated that 
DYRK1A can phosphorylate Cyclin D3 but not when T283 
is mutated to alanine (Fig. 8 G). Together, these results in-
dicate that DYRK1A destabilizes Cyclin D3 in pre–B and 
pre–T cells by phosphorylating T283.
To test whether enhanced Cyclin D3 stability was suffi-
cient to prevent cell cycle exit and differentiation in pre–B 
cells, we transduced cultured pre–B cells with retroviral con-
structs encoding the empty vector, WT Cyclin D3, or Cyclin 
D3 T283A. As expected, the T283A mutant generated much 
higher steady-state Cyclin D3 expression levels than the WT 
gene in transduced pre–B cells (Fig. 9 A). We sorted trans-
duced small pre–B cells to assess the levels of the transcripts 
that were aberrantly expressed in CKO small pre–B cells. 
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Figure 7. Loss of Dyrk1a alters pre–B cell differentiation markers without affecting pre–BCR signaling. (A and B) mRNA expression was ana-
lyzed by qRT-PCR to assess transcripts dynamically regulated during pre–B differentiation in FACS-purified large and small pre–B cells from the bone 
marrow of Dyrk1af/f Mx1-Cre (Control) and Dyrk1af/f Mx1-Cre+ (CKO) 4 wk after pI:pC treatment. PCRs were performed using cDNA from 2–3 indepen-
dently sorted pairs of mice, with 1 mouse per genotype in each pair. Error bars depict SD of triplicate wells for representative samples. (C) V-J1 light 
chain gene rearrangement was assessed by qPCR using genomic DNA from the same purified cell populations as in A and B; graph depicts mean recombi-
nation frequency as a percentage of Control small pre–B from two independent cohorts of mice, with cells pooled from two mice per genotype in each 
cohort; error bars depict SD. (D and E) Representative flow cytometry plots depicting surface pre–BCR (D) and intracellular  heavy chain expression (E) in 
pre–B cells from the bone marrow of Control and CKO mice are shown. Data are representative of three independent cohorts of mice, each with two to 
three mice per genotype. (F) Western blots were performed to assess the levels of signaling proteins in FACS-purified large and small pre–B cells from the 
bone marrow of Control and CKO mice as indicated. Data are representative of two independently sorted samples, each pooled from three mice per geno-
type. Densitometry values were normalized to Actin. (G) ERK activation was assessed by intracellular staining for phospho-ERK in large and small pre–B 
cells from the bone marrow of Control and CKO mice as indicated in the flow cytometry plot (left); (right) individual (dots) and mean (bars) percentages 
of phospho-ERK+ cells in each population are shown; n = 4 mice per genotype. Data are representative of three independent experiments. (H and I) qRT-
PCR analysis of Ccnd3 mRNA expression (H) and pre–BCR induced transcripts (I) from the same purified populations as in A and B were measured. All 
qRT-PCRs were performed using cDNA from two to three independently sorted pairs of mice, with one mouse per genotype in each pair. Error bars depict 
SD of triplicate wells for representative samples. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; NS, not significant.
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antagonized by DYRK1A during these cells’ transit from pro-
liferation to quiescence.
This study adds to a growing body of evidence that 
DYRK1A—and the DYRK family in general (Becker, 2012)—
broadly influences cell cycle entry and exit in multiple cell 
types by phosphorylating both positive and negative cell cycle 
regulators, including Cyclin D1 (Chen et al., 2013), LIN-52 
(Litovchick et al., 2011), p27 (Soppa et al., 2014), and now Cy-
clin D3. Underscoring its involvement in cell cycle regulation, 
the human DYRK1A promoter is itself bound and activated 
by E2F1 (Maenz et al., 2008), but whether this mechanism 
directs cell cycle exit by phosphorylating T283 on Cyclin 
D3 to mark the protein for degradation. Although p38 
(Casanovas et al., 2004) and GSK3 (Naderi et al., 2004), 
have been previously shown to phosphorylate T283 in cell 
lines, and T283-indpendent degradation of Cyclin D3 has 
also been reported (Låhne et al., 2006), ours is the first in vivo 
evidence that DYRK1A plays a major role in murine pre–B 
and pre–T development. A previous report found enhanced 
Cyclin D3 stability in cells that express a pre–BCR compared 
with those that do not (Cooper et al., 2006); here, we describe 
a novel regulatory mechanism by which stabilizing signals are 
Figure 8. DYRK1A destabilizes Cyclin D3 
by phosphorylating T283. (A and B) Western 
blots of FACS-purified large and small pre–B 
cells from Dyrk1af/f Mx1-Cre (Control) and 
Dyrk1af/f Mx1-Cre+ (CKO) mice 4 wk after pI:pC 
treatment were assessed for the indicated  
proteins as shown. The same membrane (cut 
into segments according to molecular weight) 
from Fig. 7 F was stripped and reprobed, 
hence the same loading control is shown 
here. Data are representative of three inde-
pendent experiments. Densitometry values 
were normalized to actin. (C) The expression 
levels of the D-type Cyclin transcripts from 
RNA-seq data (from Fig. 6) are shown for 
Control and CKO mice. (D and E) Control and 
CKO thymocytes (D), or WT cultured pre–B 
cells ± EHT 1610 (E) were treated with cyclo-
heximide (25 µg/ml) for the indicated times 
before Western blot analysis. Data are repre-
sentative of three independent experiments. 
Densitometry values were normalized to actin. 
(F) An amino acid alignment of C-terminal 
phosphodegrons in the D-type Cyclins is 
shown. Conserved residues are highlighted in 
the blue box; phosphorylated threonines are 
highlighted in the red box. (G) FLAG-tagged 
Cyclin D3 (WT or T283A) was immunoprecipi-
tated from transfected 293T cells and used for 
in vitro kinase assays with recombinant active 
DYRK1A and ATP-S. The reaction products 
were alkylated with PNBM and analyzed for 
thiophosphate esters by Western blotting. 
Data are representative of three independent 
assays. Densitometry values were normalized 
to FLAG-Cyclin D3.
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inhibition. Although our study cannot formally exclude the 
possibility that DYRK1A also phosphorylates LIN-52 and/or 
p27 during lymphoid development, it provides strong evi-
dence that Cyclin D3 is the primary DYRK1A target in these 
cells. Nonetheless, it is interesting to consider that DYRK1A 
could potentially promote cell cycle exit via at least three dis-
tinct yet ultimately convergent mechanisms: by destabilizing 
D-type Cyclins, stabilizing p27, and promoting assembly of 
the DREAM complex via LIN-52 phosphorylation.
DYRK family kinases also phosphorylate NFAT transcrip-
tion factors, triggering their export from the nucleus and thereby 
antagonizing NFAT activity (Gwack et al., 2006). Calcium 
signaling and NFAT activation play important roles in lym-
phocyte activation and differentiation (Peng et al., 2001); 
however, we did not detect any differences in NFATc2 phos-
phorylation in CKO pre–B cells (unpublished data). Furthermore, 
exists to initiate negative feedback on cell cycle entry or to 
facilitate cell cycle progression remains to be determined.
Given that DYRK1A phosphorylates multiple cell cycle 
regulators, we considered an alternative mechanism by which 
loss of DYRK1A activity might result in de-repression of 
E2F targets: a complex named DREAM (DP1, Rb-like, E2F, 
and MuvB) has been shown to silence E2F targets during qui-
escence using the repressor E2F4, and its assembly depends 
on phosphorylation of a MuvB subunit, LIN-52, on S28. 
DYRK1A can phosphorylate that site to promote DREAM 
assembly (Litovchick et al., 2011). Overexpression of WT LIN-52, 
nonphosphorylatable S28A, and phosphomimetic S28D mu-
tants did not affect the cell cycle status of pre–B cells in our 
culture system in the presence or absence of EHT 1610 (unpub-
lished data). Additionally, the phosphomimetic S28D mutant 
could not rescue the block in cell cycle exit caused by DYRK1A 
Figure 9. Expression of Cyclin D3 T283A mimics loss of DYRK1A activity. (A) Protein expression levels of FLAG-tagged Cyclin D3 retroviral con-
structs in cultured WT pre–B cells 2 d after transduction were assessed. Densitometry values were normalized to Actin. (B and C) mRNA expression levels 
of E2F target genes (B) and differentiation markers (C) were assessed by qRT-PCR in FACS-purified WT small pre–B cells after transduction with the indi-
cated constructs. RT-PCRs were performed from two independently sorted samples for each construct; error bars depict SD of triplicate wells for repre-
sentative samples. *, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant (indicated condition vs. empty vector). (D) Cell cycle analysis was performed 
in cultured WT pre–B cells after 2 d of growth conditions (5 ng/ml IL-7 and 10 ng/ml SCF) (dotted line), cell cycle exit conditions (0.05 ng/ml IL-7 and  
0.1 ng/ml SCF; shaded gray), or exit conditions in the presence of 500 nM EHT 1610 (red line). (E) Percentages of cells from (D) in S-G2-M under the indi-
cated conditions are shown; error bars depict SD of duplicate wells from a representative of four independent experiments, two of which included  
Palbociclib treatment. *, P < 0.05; ***, P < 0.001.
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of Irf4 and Ikzf3 mRNA. Likewise, these cells had less  light 
chain gene rearrangement, despite normal up-regulation of 
Rag1 transcript. Thus, our data suggest that a portion of the 
pre–B cell differentiation program, such as down-regulation 
of surrogate light chain components, up-regulation of CD2 
and CD25, and initiation of light chain rearrangements, re-
quires E2F target gene repression and cell cycle exit to be 
fully enforced, whereas another subset of pre–BCR–induced 
changes, including up-regulation of IRF4, Aiolos, and Rag1, 
does not. We have demonstrated that inhibition of Cyclin 
D3–CDK4/6 activity in CKO pre–B and pre–T cells not 
only restores cell cycle exit by facilitating E2F target gene 
repression, but it also restores aspects of differentiation that 
require cell cycle exit, including expression of markers like 
CD2 and CD25, and  light chain rearrangement. Thus, 
known NFAT target genes were not significantly enriched 
among up-regulated transcripts in any of the populations we 
analyzed by RNA-seq (unpublished data). Still, it remains 
possible that DYRK1A regulates NFATs at other stages of 
lymphoid development.
It is interesting that some outcomes of pre–BCR-induced 
differentiation seemed to occur normally amid failed cell cycle 
exit, yet others did not. For example, several studies have shown 
that pre–BCR signaling initiates a negative feedback loop, 
through which transcriptional up-regulation of Irf4 and Ikzf3 
(Aiolos) leads to transcriptional silencing of the pre–BCR 
surrogate light chain components Vpre–B and 5 (Parker 
et al., 2005; Thompson et al., 2007; Johnson et al., 2008). In 
Dyrk1a-deficient small pre–B cells, Vpre–B1 and Igll1 (5) 
transcript levels remained high, despite normal up-regulation 
Figure 10. Inhibition of CDK4/6 can 
rescue cell cycle exit and differentiation 
in Dyrk1a-defcient cells. (A) Mice of the 
indicated genotypes were treated with vehicle 
or 150 mg/kg Palbociclib (oral gavage) for  
1 wk after completion of pI:pC treatment. Cell 
cycle analysis of DP thymocytes and bone 
marrow small pre–B cells was assessed. Flow 
cytometry plots represent two independent 
experiments, each with two to three mice per 
condition. (B and C) Quantifications of mean 
quiescent DP thymocyte and small pre–B cell 
populations are shown; n = 2–3 mice per 
genotype; error bars depict SD. Data represent 
two independent experiments, each with two 
to three mice per condition. (D) qRT-PCR 
analysis was performed for the indicated 
transcripts in FACS-purified small pre–B cells 
from the mice shown in B and C. Data show 
two pooled mice per condition; error bars 
depict SD of triplicate wells. Data are repre-
sentative of two independent Palbociclib 
treatment experiments. (E) Flow cytometry 
plot depicts surface CD25 expression on bone 
marrow small pre–B cells from a representa-
tive mouse from each condition as indicated. 
Data represent two independent experiments, 
each with two to three mice per condition. 
(F) Light chain recombination frequencies 
were measured by qPCR from genomic DNA 
in FACS-purified bone marrow small pre–B 
cells from the indicated mice; each sample 
was pooled from 2 mice; data represent two 
independent experiments. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001.
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any hematologic malignancies in our CKO mice that have 
been monitored for (thus far) 12 mo after loss of Dyrk1a. 
Second, our preliminary work has shown that ALL cells un-
dergo growth inhibition and apoptosis when treated with 
DYRK1 inhibitors (unpublished data). Third, loss-of-function 
mutations in DYRK1A have not been reported in ALL; we 
have directly sequenced the gene in 12 ALL cell lines and did 
not detect any mutations, and our searches of public databases 
failed to turn up any DYRK1A mutations or silencing in 
ALL. In fact, among 3,505 sequenced primary hematopoietic 
tumor samples in the COSMIC database, only two DYRK1A 
mutations were found; both were in chronic lymphocytic 
leukemia (CLL), a mature B cell neoplasm. SIFT and PolyPhen 
software predict that both mutations (L261R and R300P) 
could be deleterious to protein function, but we are unable 
to say definitively how they might affect DYRK1A-mediated 
Cyclin D3 turnover without functional studies. Still, the over-
all scarcity of DYRK1A mutations in lymphoid leukemias 
suggests that DYRK1A activity is required for multiple as-
pects of lymphocyte biology, and that proliferative advan-
tages afforded by loss of DYRK1A (via decreased Cyclin D3 
turnover) might be offset by impairment of other DYRK1A-
dependent pathways. Our mouse data are consistent with this 
idea: despite high levels of Cyclin D3 and increased cell cycle 
entry, CKO lymphoid cells proliferate less efficiently than con-
trol counterparts. Thus, one must consider not only cell type–
specific functions of DYRK1A, but also the integration of 
multiple and potentially disparate functions within individual 
cell types.
Our study adds Cyclin D3 to a growing list of DYRK1A 
targets. We have demonstrated that normal lymphocyte devel-
opment depends on DYRK1A activity and that its loss results 
in Cyclin D3 stabilization, failure to fully repress E2F target 
genes, and inability to enter quiescence. These findings enhance 
our understanding of cell cycle regulation during lymphocyte 
differentiation and identify a previously unknown mechanism 
by which developing lymphocytes enter quiescence.
MATERIALS AND METHODS
Mice. Construction of the targeting vector to generate Dyrk1a conditional 
knockout (CKO) mice was performed as described previously (Liu et al., 
2003). In brief, a 12,273-bp genomic region obtained from the C57BL/6 
RP23 BAC library was introduced in the PL253 retrieval vector through 
homologous recombination. The loxP sites flanking exons 5 and 6, as well 
as a PGK-Neomycin cassette flanked by two FRT sites, were then sub-
cloned in this retrieval vector. After electroporation, C57BL/6 ES clones re-
sistant to G418 were screened for the targeted integration of the recombined 
allele by PCR (primer sequences available upon request). ES-recombined 
clones were then injected into Albino C57BL/6 blastocysts to generate chi-
meras. Two founding chimeric males yielded germline transmission and 
Mendelian proportions were verified by genotyping using primers forward, 
5-ATTACCTGGAGAAGAGGGCAAG-3 and reverse 5-TTCTTAT-
GACTGGAATCGTCCC-3 (primers i and ii in Fig. 1). For inducible 
pan-hematopoietic and B or T lymphocyte-specific inactivation of Dyrk1a 
gene, CKO mice were crossed with Mx1-Cre, CD19-Cre, and Lck-Cre 
strains, respectively; CD19-Cre CKO mice were subsequently crossed 
to ROSA26lox-STOP-lox-EGFP mice. Mx1-Cre, CD19-Cre, Lck-Cre, and 
ROSA26lox-STOP-lox-EGFP mice were obtained from The Jackson Laboratory. 
DYRK1A activity couples cell cycle exit to differentiation at 
these stages of development.
However, an interesting and somewhat paradoxical out-
come of DYRK1A inactivation is our finding that, despite 
high levels of Cyclin D3, Dyrk1a-deficient pre–B cells show 
severely impaired proliferative capacity: they complete fewer 
cell divisions than control cells and fail to form colonies 
ex vivo, and cannot compete with WT cells in vivo. These 
data, combined with the fact that earlier stages of B and T cell 
differentiation are also impaired by loss of DYRK1A in mixed 
bone marrow chimera experiments (Fig. 4), suggest that 
DYRK1A regulates multiple aspects of lymphocyte differen-
tiation, including some that are independent of Cyclin D3 
phosphorylation, but nonetheless affect growth, mitotic pro-
gression, or both.
A recent study found an intriguing novel role for DYRK1A, 
in which it is recruited to specific promoters, including those 
of many growth-associated genes, to phosphorylate RNAP II 
and promote transcription (Di Vona et al., 2015). Thus, a 
potential connection to our study could be that DYRK1A 
performs a similar function in developing lymphocytes to fa-
cilitate growth and proliferation; indeed, that study found high 
expression levels of genes regulated by DYRK1A in this man-
ner within lymphocyte populations. Additionally, DYRK1A 
might facilitate the mechanics of mitosis via interactions with 
cytoskeletal components: in accord with that idea, DYRK1A 
associates with multiple components of the cytoskeleton (Scales 
et al., 2009; Dowjat et al., 2012), and its overexpression can 
result in abnormal mitotic spindle formation and centrosome 
amplification (Funakoshi et al., 2003). Although the phosphory-
lation targets that mediate these effects of DYRK1A are un-
known, it remains possible that such a mechanism underlies 
the delay in G2-M progression we observed in DYRK1A-
deficient cells.
Finally, our study revisits a persistent question about the 
general nature of DYRK1A in cell growth and prolifera-
tion: is it an oncogene, a tumor suppressor, or both? Sev-
eral studies have reported that DYRK1A promotes normal 
cell proliferation (Rachdi et al., 2014) and tumor growth 
(Malinge et al., 2012), prevents apoptosis (Laguna et al., 2013; 
Barallobre et al., 2014), and enables growth factor signaling 
(Aranda et al., 2008; Pozo et al., 2013). However, equally com-
pelling studies have shown that DYRK1A suppresses prolif-
eration (Hämmerle et al., 2011; Liu et al., 2014; Soppa et al., 
2014), lengthens the time to cell cycle reentry (Chen et al., 2013), 
and promotes quiescence (Litovchick et al., 2011; Forristal 
et al., 2014). Our present work indicates that, even within 
the same cell type, DYRK1A can suppress as well as facilitate 
proliferation. The oncogene versus tumor suppressor ques-
tion is particularly relevant to this study because we have 
shown that DYRK1A promotes cell cycle exit and differen-
tiation during stages of lymphoid development that are sus-
ceptible to malignant transformation in acute lymphoblastic 
leukemia (ALL; Inaba et al., 2013). However, several lines of 
evidence suggest that DYRK1A is not a tumor suppressor, 
per se, in pre–B or pre–T cells. First, we have not detected 
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were filtered. The data were processed largely following the procedure de-
scribed in Trapnell et al. (2012). In brief, the reads were aligned to the Mus 
musculus genome (mm10) using TopHat (v2.0.8b). Subsequently, the aligned 
reads, in conjunction with a gene annotation file for mm10 obtained from 
the UCSC website, were used to determine the expression of known genes 
using Cufflinks (v2.1.1). The individual transcript files generated by Cuff-
links for each sample were merged into a single gene annotation file, which 
was then used to calculate RPKM values. Transcripts with greater than 
5 RPKM in either CKO or control conditions were kept, and the log2 ratio 
(CKO:control) was calculated. Finally, transcripts with an absolute value of 
log2 ≤ 0.9 were removed. Sequencing data are available in the Gene Expres-
sion Omnibus under accession no. GSE67052.
Functional enrichment analysis. All mRNA transcripts classified as up 
and down-regulated mRNA from each of the five cell populations were ex-
amined independently using DAVID (Huang et al., 2007). Additionally, to 
compare sets, the top 47 up or down-regulated transcripts were submitted to 
DAVID for each population and enriched terms were compared (47 was 
used because it was the minimum number of transcripts that were expressed 
at log2 > ±0.9).
qRT-PCR. Total RNA was isolated using RNeasy kits (QIAGEN) and re-
verse transcribed using SuperScript III First Strand Synthesis kits (Life Tech-
nologies). Real-time PCR was performed using PerfeCTa SYBR Green 
(Quanta Biosciences) and gene-specific primers. Data were quantified using 
the standard curve method. Quantification of V-J1 gene rearrangements 
from genomic DNA was done as previously described (Johnson et al., 2008).
Western blotting. Cells were lysed in TENT buffer (50 mM Tris, pH 8.0, 
2 mM EDTA, 150 mM NaCl, 1% Triton X-100) supplemented with 2 mM 
NaF, 2 mM NaVO3, 2 mM PMSF, and 1× cOmplete protease inhibitor 
cocktail (Roche) for 30 min on ice. Insoluble debris was pelleted by centrif-
ugation at 21,000 g for 10 min at 4°C. Lysates were denatured in LDS sample 
loading buffer (Life Technologies) at 100°C for 5 min, and electrophoresed 
on 4–12% Bis-Tris gradient gels (Life Technologies). Proteins were transferred 
to PVDF membranes and probed with primary antibodies for: DYRK1A 
(7D10; Abnova), Cyclin D3 (C-16; Santa Cruz Biotechnology, Inc.), Cyclin 
D2 (M-20; Santa Cruz Biotechnology, Inc.), phospho-RB S807/811 
(D20B12; Cell Signaling Technology), phospho-Src family Y461 (D49G4; 
Cell Signaling Technology), phospho-PDK1 S241 (C49H2; Cell Signaling 
Technology), Lyn (5G2, Cell Signaling Technology), phospho-NFATc2 
S326 (sc-32994; Santa Cruz Biotechnology, Inc.), and FLAG (M2; Sigma-
Aldrich) and detected with HRP-conjugated secondary antibodies and ECL 
substrate (GE Healthcare). -Actin was detected using an HRP-conjugated 
primary antibody (C4; Santa Cruz Biotechnology, Inc.). Band densitometry 
values were calculated using ImageJ software.
Plasmids and site-directed mutagenesis. Coding sequences for Cyclin 
D3 and LIN-52 were amplified by PCR from mouse pre–B cell cDNA 
using high-fidelity Pfu Ultra polymerase (Agilent Technologies) and ligated 
into the p3XFLAG-CMV7.1 expression vector (Sigma-Aldrich). Site-directed 
mutagenesis was performed using QuikChange kits (Agilent Technologies), 
and sequences were verified by direct DNA sequencing. 3xFLAG-tagged 
Cyclin D3 and LIN-52 cDNAs were amplified by PCR and subcloned into 
the MIGR1 retroviral vector.
Kinase assays. Nonradioactive assays were performed as described previ-
ously (Allen et al., 2007). In brief, 293T cells were transfected with p3xFLAG-
CMV7.1-Cyclin D3 WT or T283A and lysed 2 d later for immunoprecipitation 
with anti-FLAG affinity gel (Sigma-Aldrich). Bead-bound Cyclin D3 
immunoprecipitates were washed extensively, and then added to kinase reac-
tions containing a recombinant active fragment of hDYRK1A (Millipore), 
ATP-S (Abcam), and kinase assay buffer (40 mM Tris, pH 7.5, 10 mM 
MgCl2, and 50 mM NaCl). Reactions were incubated on a rotator at room 
temperature for 45 min, before adding 25 mM p-nitrobenzyl mesylate (PNBM; 
Mice were maintained in specific pathogen–free conditions. All in vivo 
experiments were approved by the Northwestern University Institutional 
Animal Care and Use Committee.
For all experiments, mice were analyzed between 5–10 wk of age. Lit-
termate controls were used for each analysis cohort.
pI:pC administration. To induce Cre expression in Mx1-Cre mice, ani-
mals received intraperitoneal injections of pI:pC (20 µg/gram of body 
weight; InvivoGen) every other day for a total of 4 injections. Injections 
began when mice were 3–6 wk of age.
Flow cytometry and cell sorting. Single-cell suspensions of bone mar-
row and thymocytes were prepared and stained in FACS buffer (PBS + 
3% FBS) containing fluorochrome-conjugated antibodies for surface markers, 
including B220 (RA3-6B2; eBioscience), CD43 (S7; BD), IgM (II/41; 
eBioscience), IgD (11-26c-2a; BD), cKit (2B8; eBioscience), IL7Ra (A7R34; 
eBioscience), CD25 (PC61.5; eBioscience), Gr1 (RB6-8C5; BD), Mac1/
CD11b (M1/70; eBioscience), and pre–BCR (SL156; BD). Apoptotic cells 
were quantified using Annexin V (BD) and cleaved Caspase 3 (BioLegend) 
staining kits.
For intracellular staining, cells were stained for surface markers, washed 
with FACS buffer, fixed for 30 min with Cytofix fixation buffer (BD), 
washed, permeabilized with ice-cold Perm Buffer iii (BD), washed again, 
and then stained with fluorochrome-conjugated antibodies against intra-
cellular proteins, including: phospho-STAT5 Y694 (D47E7; Cell Signaling 
Technology), phospho-ERK1/2 T202/Y204 (197G2; Cell Signaling Tech-
nology), or IgM (II/41; eBioscience).
For cell cycle analysis, cells were first incubated with 10 µg/ml Hoechst 
33342 (Life Technologies) for 1 h at 37°C, washed, then stained for surface 
markers on ice for 30 min, washed, fixed for 30 min on ice, washed, and 
finally resuspended in FACS buffer containing 1 µg/ml Pyronin Y (Sigma-
Aldrich) before analysis. Cells were analyzed on a LSRII cytometer (BD).
For cell cycle–based sorting, cells were first incubated with Hoechst 
33342 (2 µg/ml) for 1 h at 37°C, washed, stained for surface markers on ice 
for 30 min, washed, and resuspended in FACS buffer containing 1 µg/ml 
Pyronin Y and 2 µg/ml Hoechst 33342. Quiescent (Pyronin Ylow, 2N DNA 
content) and cycling (Pyronin Yhigh, >2N DNA content) cells were purified 
using BD FACS Aria cell sorters. Gating strategies were similar to those de-
picted in Figs. 2 and 4 A.
BrdU incorporation. Mice were given intraperitoneal injections of BrdU 
(150 mg) and sacrificed 24 h later. Bone marrow and thymocytes were 
stained for surface markers, and then analyzed for BrdU incorporation and 
DNA content using BrdU Flow kits (BD).
Colony assays. For pre–B colony assays, 200,000 total bone marrow cells were 
plated in M3630 medium; for myeloid colony assays, 25,000 total bone 
marrow cells were plated in M3434 medium (both media from Stem Cell 
Technologies) and incubated at 37°C, 5% CO2. For inhibitor treatments, EHT 
1610 or vehicle was added directly to the medium and vortexed vigorously 
before plating the cells. Colony numbers and phenotypes were scored 7 d later.
Library construction and sequencing. Library construction and se-
quencing (100 bp, paired-end) were performed by Beijing Genomics Insti-
tute. The total RNA samples were first treated with DNase I and then 
enriched for mRNA with oligo(dT) magnetic beads. After fragmentation, 
first strand of cDNA was synthesized using random hexamer primer. Double-
stranded cDNA was purified with magnetic beads and end reparation and 
3-end single nucleotide A (adenine) addition were then performed. Finally, 
sequencing adaptors were ligated to the fragments and DNA fragments were 
enriched by PCR amplification. Library products were sequenced on the 
Illumina HiSeq2000.
Transcriptome analysis. The quality of DNA reads, in Fastq format, was 
evaluated using FastQC. Adapters were removed and reads of poor quality 
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Abcam) for 2 h to alkylate thiophosphates. Reaction products were subjected to 
Western blot and probed with an anti-thiophosphate ester antibody (51–8; 
Abcam) to visualize phosphorylated proteins.
Retrovirus production. 293T cells were grown to 70–80% confluence in 
10-cm dishes and transfected with 10 µg of MIGR1 plasmid and 10 µg of 
Eco packaging plasmid using Xtreme Gene 9 (Roche). Fresh medium was 
replaced after 12 h. Retrovirus-containing supernatants were collected 
24-48 h after transfection, 0.45-µm filtered to remove cell debris, and frozen 
at 80°C until use. Thawed supernatants were used at a 2:1 ratio with fresh 
medium for transductions.
Pre–B cell cultures. CD19+ cells were positively selected from suspensions 
of total bone marrow mononuclear cells using EasySep kits (Stem Cell Tech-
nologies), and expanded in DMEM (supplemented with 10% FBS [Hyclone], 
2 mM l-glutamine, 10 mM Hepes, 1 mM sodium pyruvate, 1× Primocin 
[InvivoGen], and 55 µM -mercaptoethanol) containing 5 ng/ml IL-7 and 
10 ng/ml SCF (PeproTech) for 4–5 d, replating in fresh medium every 2 d. 
Retroviral transductions were performed by centrifuging the cells at 700 g 
for 1 h in the presence of retroviral supernatant and 8 µg/ml polybrene 
(Millipore), and then incubated for an additional 4–6 h before replating in 
fresh medium. Experiments were performed 2 d after transduction. For cell 
cycle exit experiments, cells were replated in either the above medium 
(growth conditions), or the same base medium containing 0.05 ng/ml IL-7 
and 0.1 ng/ml SCF (exit conditions) for 2 additional days. Palbociclib was 
purchased from Selleckchem.
In vivo Palbociclib treatments. Control and CKO mice were treated 
with pI:pC as described above; then, Palbociclib treatment was initiated one 
week after the last pI:pC injection. Mice received 30 or 150 mg/kg Palboci-
clib (in 50 mM sodium lactate) via oral gavage once daily for 7 d. Mice were 
analyzed 1 d after completion of the treatment protocol.
Statistical analysis. Data were analyzed by Student’s t test (unpaired, two-
tailed). Statistically significant differences are indicated in each figure, with 
corresponding p-values in each figure legend.
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